Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding trial of ofatumumab in relapsing-remitting multiple sclerosis
2007-004223-38Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ofatumumab in relapsing-remitting multiple sclerosis (RRMS) (4 arms), sponsored by GSK. Primary endpoint: Cumulative number of new gadolinium-enhancing lesions on T1-weighted MRI from week 8 to week 24. Started Nov 2007; status: completed.
02
Drugs
ofatumumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2007-004223-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004223-38.